PML enhances the regulation of p53 by CK1 in response to DNA damage

Oncogene

Volumn 27, Issue 26, 2008, Pages 3653-3661

  Alsheich Bartok, O ^a   Haupt, S ^a   Alkalay Snir, I ^a   Saito, S ^b   Appella, E ^b   Haupt, Y ^a  

^a HEBREW UNIVERSITY   (Israel)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CK1; Mdm2; p53; PML; Threonine 18 phosphorylation

Indexed keywords

CASEIN KINASE I; CASEIN KINASE IDELTA; CASEIN KINASE IEPSILON; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; THREONINE; ARSENIC TRIOXIDE; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; PML PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; HUMAN; HUMAN CELL; NUCLEAR IMPORT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; ACTIVE TRANSPORT; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ARSENICALS; CASEIN KINASE I; CELL LINE, TUMOR; DNA DAMAGE; HUMANS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OXIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-MDM2; THREONINE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 45949110751     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1211036     Document Type: Article

References (30)

1. Behrend L, Milne DM, Stöter M, Deppert W, Campbell LE, Meek DW et al. (2000). IC261, a specific inhibitor of the protein kinases casein kinase 1-delta and -epsilon, triggers the mitotic checkpoint and induces p53-dependent postmitotic effects. Oncogene 19: 5303-5313.
2. Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, Hupp TR. (1999). Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342(Pt 1): 133-141.
3. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G et al. (2004). PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13: 523-535.
4. Dumaz N, Milne DM, Meek DW. (1999). Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett 463: 312-316.
5. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al. (2004). Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96: 269-279.
6. Hoekstra MF, Dhillon N, Carmel G, DeMaggio AJ, Lindberg RA, Hunter T et al. (1994). Budding and fission yeast casein kinase I isoforms have dual-specificity protein kinase activity. Mol Biol Cell 5: 877-886.
7. Iwakuma T, Lozano G. (2003). MDM2, an introduction. Mol Cancer Res 1: 993-1000.
8. Knippschild U, Gocht A, Wolff S, Huber N, Löhler J, Stöter M. (2005). The casein kinase 1 family: participation in multiple cellular processes in eukaryotes. Cell Signal 17: 675-689.
9. Knippschild U, Milne DM, Campbell LE, DeMaggio AJ, Christenson E, Hoekstra MF et al. (1997). p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerase-directed drugs. Oncogene 15: 1727-1736.
10. Lai Z, Auger KR, Manubay CM, Copeland RA. (2000). Thermodynamics of p53 binding to hdm2 (1-126): effects of phosphorylation and p53 peptide length. Arch Biochem Biophys 381: 278-284.
11. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. (2002). Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 21: 2383-2396.
12. Lavin MF, Gueven N. (2006). The complexity of p53 stabilization and activation. Cell Death Differ 13: 941-950.
13. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. (2003). The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 278: 33134-33141.
14. Marine JC, Dyer MA, Jochemsen AG. (2007). MDMX: from bench to bedside. J Cell Sci 120: 371-378.
15. Maritzen T, Lohler J, Deppert W, Knippschild U. (2003). Casein kinase I delta (CKIdelta)is involved in lymphocyte physiology. Eur J Cell Biol 82: 369-378.
16. Mashhoon N, DeMaggio AJ, Tereshko V, Bergmeier SC, Egli M, Hoekstra MF et al. (2000). Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem 275: 20052-20060.
17. Meek DW. (2004). The p53 response to DNA damage. DNA Repair (Amst) 3: 1049-1056.
18. Muller S, Miller Jr WH, Dejean A. (1998). Trivalent antimonials induce degradation of the PML-RAR oncoprotein and reorganization of the promyelocytic leukemia nuclear bodies in acute promyelocytic leukemia NB4 cells. Blood 92: 4308-4316.
19. Rizzo MG, Zepparoni A, Cristofanelli B, Scardigli R, Crescenzi M, Blandino G et al. (1998). Wt-p53 action in human leukaemia cell lines corresponding to different stages of differentiation. Br J Cancer 77: 1429-1438.
20. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace Jr AJ et al. (2003). Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem 278: 37536-37544.
21. Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW, Appella E. (2000). Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding. J Biol Chem 275: 9278-9283.
22. Salomoni P, Pandolfi PP. (2002). p53 De-ubiquitination: at the edge between life and death. Nat Cell Biol 4: E152-E153.
23. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR. (2002). Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323: 491-501.
24. Sionov RV, Coen S, Goldberg Z, Berger M, Bercovich B, Ben-Neriah Y et al. (2001). c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination. Mol Cell Biol 21: 5869-5878.
25. Soubeyrand S, Schild-Poulter C, Haché RJ. (2004). Structured DNA promotes phosphorylation of p53 by DNA-dependent protein kinase at serine 9 and threonine 18. Eur J Biochem 271: 3776-3784.
26. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. (2006). Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441: 523-527.
27. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C et al. (1998). Role of PML in cell growth and the retinoic acid pathway. Science 279: 1547-1551.
28. Wolff S, Stoter M, Giamas G, Piesche M, Henne-Bruns D, Banting G et al. (2006). Casein kinase 1 delta (CK1delta) interacts with the SNARE associated protein snapin. FEBS Lett 580: 6477-6484.
29. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY et al. (1997). Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94: 3978-3983.
30. Zimber A, Nguyen QD, Gespach C. (2004). Nuclear bodies and compartments: functional roles and cellular signaling in health and disease. Cell Signal 16: 1085-1104.